SAB Biotherapeutics, Inc. (SABS) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for SAB Biotherapeutics, Inc. (SABS).

Download StockRank on Google Play Download StockRank on the App Store

Equity Overview

Price & Market Data

Price: $3.76

Daily Change: $0.00 / 0.00%

Daily Range: $0 - $0

Market Cap: $264,236,672

Daily Volume: 0

Performance Metrics

1 Week: -0.53%

1 Month: -0.79%

3 Months: 0.53%

6 Months: 82.52%

1 Year: 238.7%

YTD: 0.53%

Company Details

Employees: 86

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Selected stocks

Colombier Acquisition Corp. III (CLBR)

Regentis Biomaterials Ltd. (RGNT)

Spartacus Acquisition Corp. II (TMTS)